Quarterly ResultMay 7, 2026, 08:37 AM
Cadrenal Therapeutics Q1 Net Loss $2.5M; Going Concern Doubt Raised
AI Summary
Cadrenal Therapeutics reported a net loss of $2.5 million for the first quarter of 2026, an improvement from $3.8 million in the same period last year. The company's cash and cash equivalents stood at $2.3 million as of March 31, 2026, a decrease from $4.0 million at the end of 2025. Management expressed substantial doubt about the company's ability to continue as a going concern due to ongoing operating losses and expected capital needs. To address this, the company plans to raise additional funds through partnering, equity, and debt financings, and generated $1.3 million in net proceeds from its ATM facility during the quarter.
Key Highlights
- Net loss for Q1 2026 was $2.5 million, an improvement from $3.8 million in Q1 2025.
- Basic and diluted net loss per share was $(1.04) in Q1 2026, compared to $(2.09) in Q1 2025.
- Cash and cash equivalents decreased to $2.3 million as of March 31, 2026, from $4.0 million at December 31, 2025.
- Net cash used in operating activities was $3.0 million for Q1 2026, down from $4.6 million in Q1 2025.
- Total operating expenses decreased to $2.5 million in Q1 2026 from $3.9 million in Q1 2025.
- Sold 168,690 common shares through ATM facility for net proceeds of $1.3 million in Q1 2026.
- Management identified substantial doubt about the company's ability to continue as a going concern.